A new study reveals how aggressive triple-negative breast cancer (TNBC) evades the body’s immune defenses. Researchers discovered that TNBC tumors produce a specific protein, interleukin-1 beta (IL-1β), which reprograms the tumor microenvironment. This process deactivates nearby immune cells, specifically cytotoxic T-cells, that would normally attack the cancer. The findings, based on both mouse models and human tumor analysis, identify IL-1β signaling as a key mechanism of immunosuppression. This discovery provides a potential new therapeutic target, suggesting that blocking IL-1β could restore the immune system’s ability to fight this aggressive cancer. Read the full article at https://www.sciencedaily.com/releases/2026/04/260411022031.htm